%0 Journal Article
%T CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases.
%A Chevalier K
%A Genin M
%A Jean TP
%A Avouac J
%A Flipo RM
%A Georgin-Lavialle S
%A El Mahou S
%A Pertuiset E
%A Pham T
%A Servettaz A
%A Marotte H
%A Domont F
%A Chazerain P
%A Devaux M
%A Mekinian A
%A Sellam J
%A Fautrel B
%A Rouzaud D
%A Ebstein E
%A Costedoat-Chalumeau N
%A Richez C
%A Hachulla E
%A Mariette X
%A Seror R
%J Front Med (Lausanne)
%V 10
%N 0
%D 2023
%M 37035330
%F 5.058
%R 10.3389/fmed.2023.1152587
%X <B>UNASSIGNED: </B>Autoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed to identify factors associated with occurrence of severe COVID-19 in AIRD patients and to evaluate whether having an AIRD was associated with increased risk of severe COVID-19 or death.<BR><B>UNASSIGNED: </B>Two databases were analyzed: the EDS (Entrepôt des Données de Santé, Clinical Data Warehouse), including all patients followed in Paris university hospitals and the French multi-center COVID-19 cohort [French rheumatic and musculoskeletal diseases (RMD)]. First, in a combined analysis we compared patients with severe and non-severe COVID-19 to identify factors associated with severity. Then, we performed a propensity matched score case-control study within the EDS database to compare AIRD cases and non-AIRD controls.<BR><B>UNASSIGNED: </B>Among 1,213 patients, 195 (16.1%) experienced severe COVID-19. In multivariate analysis, older age, interstitial lung disease (ILD), arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory diseases, and treatment with corticosteroids or rituximab were associated with increased risk of severe COVID-19. Among 35,741 COVID-19 patients in EDS, 316 having AIRDs were compared to 1,264 Propensity score-matched controls. AIRD patients had a higher risk of severe COVID-19 [aOR = 1.43 (1.08-1.87), p = 0.01] but analysis restricted to rheumatoid arthritis and spondyloarthritis found no increased risk of severe COVID-19 [aOR = 1.11 (0.68-1.81)].<BR><B>UNASSIGNED: </B>In this multicenter study, we confirmed that AIRD patients treated with rituximab or corticosteroids and/or having vasculitis, auto-inflammatory disease, and sarcoidosis had increased risk of severe COVID-19. Also, AIRD patients had, overall, an increased risk of severe COVID-19 compares general population.